Roche Holding Ltd ADR

Roche develops and sells prescription medicines for serious diseases—primarily cancer, autoimmune conditions, neurological disorders, and infectious diseases—while also manufacturing diagnostic instruments and laboratory tests that help doctors detect illnesses early [Yahoo Finance]. The company operates two main divisions: pharmaceuticals (drugs) and diagnostics (medical tests and equipment), serving hospitals, clinics, and laboratories across six continents.

Roche Holding is a Swiss pharmaceutical and diagnostics giant with over 103,000 employees, generating $63.4B in annual revenue from medicines treating cancer, autoimmune diseases, and infectious conditions, plus diagnostic tests for diseases like COVID-19 and hepatitis [Yahoo Finance]. The company recently won FDA approval to expand its blockbuster cancer drug Tecentriq into bladder cancer and is advancing a promising experimental breast cancer treatment called giredestrant [Yahoo Finance]. Financially, Roche stands on rock-solid footing with a health score of 8.9/10, strong free cash flow of $13.1B, and minimal net debt at just 0.6x EBITDA [Yahoo Finance] [Sentinellis calculation].

Roche is financially robust with excellent profitability, minimal debt, and very strong cash generation.